News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
736,993 Results
Type
Article (41692)
Company Profile (308)
Press Release (694977)
Multimedia
Podcasts (90)
Webinars (20)
Section
Business (207198)
Career Advice (2043)
Deals (35893)
Drug Delivery (128)
Drug Development (82571)
Employer Resources (175)
FDA (16535)
Job Trends (15114)
News (350612)
Policy (32955)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2601)
Accelerated approval (45)
Adcomms (26)
Allergies (170)
Alliances (50233)
ALS (206)
Alzheimer's disease (1780)
Antibody-drug conjugate (ADC) (433)
Approvals (16916)
Artificial intelligence (644)
Autoimmune disease (263)
Automation (53)
Bankruptcy (362)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (206)
Bladder cancer (185)
Brain cancer (71)
Breast cancer (736)
Cancer (5711)
Cardiovascular disease (467)
Career advice (1731)
Career pathing (41)
CAR-T (321)
CDC (55)
Celiac Disease (3)
Cell therapy (860)
Cervical cancer (46)
Clinical research (71519)
Collaboration (2041)
Company closure (5)
Compensation (1363)
Complete response letters (77)
COVID-19 (2745)
CRISPR (104)
C-suite (1091)
Cystic fibrosis (152)
Data (7621)
Decentralized trials (3)
Denatured (27)
Depression (160)
Dermatology (78)
Diabetes (578)
Diagnostics (6911)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (312)
Drug pricing (199)
Drug shortages (31)
Duchenne muscular dystrophy (275)
Earnings (92425)
Editorial (65)
Employer branding (22)
Employer resources (154)
Events (121317)
Executive appointments (1080)
FDA (20182)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1689)
Gene editing (225)
Generative AI (54)
Gene therapy (690)
GLP-1 (1049)
Government (4733)
Grass and pollen (7)
Guidances (403)
Healthcare (19020)
HIV (78)
Huntington's disease (56)
IgA nephropathy (93)
Immunology and inflammation (283)
Immuno-oncology (87)
Indications (177)
Infectious disease (3080)
Inflammatory bowel disease (208)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (287)
Interviews (322)
IPO (16848)
IRA (50)
Job creations (3693)
Job search strategy (1439)
JPM (58)
Kidney cancer (18)
Labor market (96)
Layoffs (563)
Leadership (37)
Legal (7980)
Liver cancer (99)
Longevity (33)
Lung cancer (755)
Lymphoma (423)
Machine learning (60)
Management (59)
Manufacturing (1007)
MASH (183)
Medical device (13914)
Medtech (14016)
Mergers & acquisitions (20277)
Metabolic disorders (1473)
mRNA (195)
Multiple sclerosis (186)
NASH (17)
Neurodegenerative disease (406)
Neuropsychiatric disorders (104)
Neuroscience (3265)
Neurotech (1)
NextGen: Class of 2026 (6548)
Non-profit (4543)
Now hiring (76)
Obesity (688)
Opinion (285)
Ovarian cancer (210)
Pain (249)
Pancreatic cancer (291)
Parkinson's disease (354)
Partnered (33)
Patents (585)
Patient recruitment (654)
Peanut (61)
People (60186)
Pharmaceutical (70)
Pharmacy benefit managers (32)
Phase 1 (22322)
Phase 2 (31552)
Phase 3 (23362)
Pipeline (8028)
Policy (308)
Postmarket research (2573)
Preclinical (9511)
Press Release (64)
Prostate cancer (292)
Psychedelics (52)
Radiopharmaceuticals (328)
Rare diseases (1043)
Real estate (6054)
Recruiting (71)
Regulatory (25469)
Reports (55)
Research institute (2425)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (178)
Series A (282)
Series B (208)
Service/supplier (11)
Sickle cell disease (109)
Special edition (22)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3680)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (61)
Vaccines (1088)
Venture capital (105)
Weight loss (442)
Women's health (121)
Worklife (20)
Date
Today (171)
Last 7 days (831)
Last 30 days (2822)
Last 365 days (30463)
2026 (10870)
2025 (30428)
2024 (35556)
2023 (40469)
2022 (51632)
2021 (56241)
2020 (54468)
2019 (46897)
2018 (35311)
2017 (32507)
2016 (31946)
2015 (38016)
2014 (31842)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (750)
Alabama (96)
Alaska (7)
Arizona (345)
Arkansas (15)
Asia (40596)
Australia (6604)
California (12905)
Canada (3688)
China (1341)
Colorado (552)
Connecticut (559)
Delaware (393)
Europe (88502)
Florida (1956)
Georgia (412)
Hawaii (3)
Idaho (62)
Illinois (1029)
India (89)
Indiana (587)
Iowa (23)
Japan (519)
Kansas (129)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1557)
Massachusetts (9256)
Michigan (355)
Minnesota (699)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (84)
New Jersey (3422)
New Mexico (29)
New York (3404)
North Carolina (1693)
North Dakota (8)
Northern California (6433)
Ohio (382)
Oklahoma (23)
Oregon (42)
Pennsylvania (2594)
Puerto Rico (29)
Rhode Island (50)
South America (1125)
South Carolina (85)
South Dakota (2)
Southern California (5084)
Tennessee (207)
Texas (2041)
United States (45774)
Utah (383)
Vermont (1)
Virginia (312)
Washington D.C. (80)
Washington State (1053)
West Virginia (4)
Wisconsin (126)
Wyoming (2)
736,993 Results for "henlius biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026
April 23, 2026
·
2 min read
Press Releases
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
April 29, 2026
·
8 min read
Press Releases
Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22
March 2, 2026
·
2 min read
Press Releases
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
·
19 min read
Press Releases
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
October 23, 2025
·
4 min read
Press Releases
Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer
December 10, 2025
·
2 min read
Press Releases
Servier completes the acquisition of Day One Biopharmaceuticals
April 23, 2026
·
2 min read
Press Releases
Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.
April 23, 2025
·
1 min read
Press Releases
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 19, 2025
·
9 min read
Press Releases
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
July 1, 2025
·
4 min read
1 of 73,700
Next
